PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors

被引:53
|
作者
Skalsky, YM
Ajuh, PM
Parker, C
Lamond, AI
Goodwin, G
Cooper, CS
机构
[1] Inst Canc Res, Mol Carcinogenesis Sect, Haddow Labs, Sutton SM2 5NG, Surrey, England
[2] Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland
基金
英国惠康基金;
关键词
TFE3; PRCC; transcription activation; pre-mRNA splicing;
D O I
10.1038/sj.onc.1204056
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In papillary renal cell carcinomas the TFE3 transcription factor becomes fused to the PSF and NonO pre-mRNA splicing factors and most commonly to a protein of unknown function designated PRCC, In this: study we have examined the ability of the resulting PRCC-TFE3 and NonO-TFE3 fusions to activate transcription from the plasminogen activator inhibitor-1 (PAI-1) promoter. The results shea that only fusion to PRCC enhanced transcriptional activation, indicating that the ability to enhance the level of transcription from endogenous TFE3 promoters is not a consistent feature of TFE3 fusions, In investigations of the normal function of PRCC,ve observed that PRCC expressed as a green fluorescent fusion protein colocalizes within the nucleus with Sm pre-RNA splicing factors. It was also found that endogenous PRCC is coimmunoprecipitated by antibodies that recognize a variety of pre-mRNA splicing factors including SC35, PRL1 and CDC5. Association with the cellular splicing machinery is therefore, a common feature of the proteins that become fused to TFE3 in papillary renal cell carcinomas.
引用
收藏
页码:178 / 187
页数:10
相关论文
共 50 条
  • [1] PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors
    Y M Skalsky
    P M Ajuh
    C Parker
    A I Lamond
    G Goodwin
    C S Cooper
    Oncogene, 2001, 20 : 178 - 187
  • [2] Clinicopathological and prognostic significance of TFE3 in papillary renal carcinoma (PRCC)
    Takamatsu, Dai
    Kohashi, Kenichi
    Kiyozawa, Daisuke
    Takeuchi, Ario
    Inokuchi, Junichi
    Eto, Masatoshi
    Oda, Yoshinao
    CANCER SCIENCE, 2022, 113 : 1583 - 1583
  • [3] Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins
    Marian J Weterman
    Jan JM van Groningen
    Aswin Jansen
    Ad Geurts van Kessel
    Oncogene, 2000, 19 : 69 - 74
  • [4] Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins
    Weterman, MAJ
    von Groningen, JJM
    Jansen, A
    van Kessel, AG
    ONCOGENE, 2000, 19 (01) : 69 - 74
  • [5] Clinicopathological and prognostic significance of TFE3 in papillary renal carcinoma
    Takamatsu, T.
    Kenichi, K.
    Daisuke, K.
    Fumio, K.
    Masaki, S.
    Yoshinao, O.
    Masatoshi, E.
    EUROPEAN UROLOGY, 2021, 79 : S738 - S738
  • [6] Transformation capacities of the papillary renal cell carcinoma-associated PRCCTFE3 and TFE3PRCC fusion genes
    Weterman, MAJ
    van Groningen, JJM
    den Hartog, A
    van Kessel, AG
    ONCOGENE, 2001, 20 (12) : 1414 - 1424
  • [7] Transformation capacities of the papillary renal cell carcinoma-associated PRCCTFE3 and TFE3PRCC fusion genes
    Marian A J Weterman
    Jan J M van Groningen
    Anita den Hartog
    Ad Geurts van Kessel
    Oncogene, 2001, 20 : 1414 - 1424
  • [8] Renal cell carcinoma associated with TFE3 gene fusion in an elderly woman
    LaGrange, Chad A.
    Lele, Subodh M.
    Strup, Stephen E.
    UROLOGY, 2007, 70 (03) : 590.e11 - 590.e12
  • [9] Fusion of splicing factor genes PSF and NonO (p54(nrb)) to the TFE3 gene in papillary renal cell carcinoma
    Clark, J
    Lu, YJ
    Sidhar, SK
    Parker, C
    Gill, S
    Smedley, D
    Hamoudi, R
    Linehan, WM
    Shipley, J
    Cooper, CS
    ONCOGENE, 1997, 15 (18) : 2233 - 2239
  • [10] Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma
    Jeremy Clark
    Yong-Jie Lu
    Sanjiv K Sidhar
    Chris Parker
    Sandra Gill
    Damian Smedley
    Rifat Hamoudi
    W Marston Linehan
    Janet Shipley
    Colin S Cooper
    Oncogene, 1997, 15 : 2233 - 2239